News

Tomato genome decoded
Enlarge image

ResearchUKSpainBelgiumItaly

Tomato genome decoded

31.05.2012 - Researchers have decoded the tomato genome, laying the foundation for smart breeding of other species of the solanaceae family.

Ghent, Rome, Harpenden, Washington – A consortium of 300 researchers from 14 countries has decoded 80% of the tomato genome, and 90% of its 35,000 protein-coding genes. The leaders of the UK arm of the Tomato Genome Consortium (TGC), Graham Seymour at the University of Nottingham and Gerard Bishop, formerly of Imperial College London, stressed the sequence will make precision breeding possible not just in tomatoes, but also in other crop species from the Solanaceae or nightshade family, such as aubergines and peppers.

They said it could help to develop tomato varieties that can survive pests, pathogens and even climate change, as well as high-yield crops that still have a good flavour. “It’s really all about making a better tomato,” commented Allen Van Deynze, a molecular geneticist at the Seed Biotechnology Center at the University of California, Davis. “This work enables a lot of things we just couldn’t do before.”

 The researchers compared the sequences a domesticated tomato variety used to produce the famous ketchup („Heinz1706“) and its closest wild relative, /Solanum pimpinellifolium/ and its functional consequences.  "For any characteristic of the tomato, whether it's taste, natural pest resistance or nutritional content, we've captured virtually all those genes," said James Giovannoni from the Boyce Thompson Institute for Plant Research at Cornell University, who was part of the U.S. tomato sequencing team.  The research also offers some insight into how the tomato ripens and how its relatives diversified and adapted to new environments.  Using traditional Sanger sequencing, the TGC started its work in 2003 but the genome sequence still had major holes by 2008. Next generation sequencing helped the consortium to close the gaps and to translate the genetic information into biological functions. Belgian experts from VIB and University Ghent mainly lead the gene prediction that translated the raw genome sequence in biological knowledge.

http://www.european-biotechnology-news.com/news/news/2012-02/tomato-genome-decoded.html

BusinessBelgiumSpain

31.07.2015 Spanish business developer Genetrix has sold its clinical stage cell therapy development subsidiary Coretherapix to Belgian TiGenix in a deal worth up to €267m.

BusinessUKSwitzerland

29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.

M&AIreland

28.07.2015 Irish Allergan is bolstering its product pipeline with a takeover of CNS specialist Naurex. At the same time, the company is divesting its global generics business to Teva.

Public marketGermanyFranceBelgiumFinlandDenmarkUK

24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.

FinanceFrance

23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.

BioplasticsFrance

21.07.2015 French biotech Deinove has launched a R&D programme to produce the versatile chemical intermediate muconic acid by using a designer variant of the Deinococcus bacteria.

BusinessFrance

16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.

R&DUK

15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.

FundingUK

13.07.2015 UK drug developer ReNeuron has pulled in £68.4m (€96m) for its cell therapy pipeline for stroke and blindness treatments. Biotech guru Neil Woodford increases his fund’s stake in ReNeuron.

BusinessSweden

10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.23 EUR43.75%
  • DIAXONHIT (F)0.79 EUR14.49%
  • ACTIVE BIOTECH (S)12.35 SEK10.27%

FLOP

  • ZELTIA (E)3.69 EUR-8.44%
  • SWEDISH ORPHAN BIOVITRUM (S)13.05 USD-6.12%
  • ALMIRALL (E)17.75 EUR-5.84%

TOP

  • DBV TECHNOLOGIES (F)79.24 EUR46.0%
  • IXICO (UK)34.00 GBP44.7%
  • BIOTIE THERAPEUTICS (FI)0.23 EUR43.8%

FLOP

  • BIOTEST (D)25.52 EUR-63.6%
  • BIOTECH PHARMACON (N)9.45 NOK-46.0%
  • TRANSGENE (F)2.87 EUR-24.5%

TOP

  • ADOCIA (F)86.78 EUR577.4%
  • FORMYCON (D)28.40 EUR323.2%
  • DBV TECHNOLOGIES (F)79.24 EUR317.5%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-88.9%
  • NEUROVIVE PHARMACEUTICAL AB (S)22.10 SEK-70.6%
  • NEOVACS (F)1.02 EUR-68.6%

No liability assumed, Date: 01.08.2015